UK authorizes Moderna vaccine targeting Covid-19 Omicron

The United Kingdom’s pharmaceuticals regulator announced Monday that it had authorized a modified coronavirus vaccine targeting both the Omicron variation and the original type.

The Medicine and Healthcare products Regulatory Agency (MHRA) stated in a press release that it had authorized the vaccine for adult booster doses “after determining that it met the UK regulator’s safety, quality, and effectiveness standards.”

It was the first “bivalent” Covid-19 vaccine to receive British regulatory approval.

June Raine, the chief executive officer of the MHRA, stated that evidence from a clinical trial demonstrated it elicited a “strong immune response” against the original virus and Omicron and would give a “honed weapon” as the virus continued to evolve.